drugset / Trial / NCT01939184
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of various fixed daily doses of WC3055 compared with placebo for the treatment of subjects with LUTS secondary to BPH.
Timeline
- Start
- 2013-08
- Primary completion
- 2014-03
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | WC3055 | Unknown | 12.5 mg | — |
| Subject | WC3055 | Unknown | 25 mg | — |
| Subject | WC3055 | Unknown | 50 mg | — |
| Subject | WC3055 | Unknown | 75 mg | — |